



CORRESPONDENCE

Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia

To the Editors:

We read with interest the recent paper by RESTREPO *et al.* [1] who reported that adding a macrolide to the antibiotic regimen in patients with community-acquired pneumonia (CAP) and severe sepsis resulted in lower mortality. Their data are very promising. However, we have a concern regarding the recommendations to implement macrolides as standard treatment for CAP.

Treatment with macrolides has been shown to have beneficial effects in chronic inflammatory airway diseases such as diffuse panbronchiolitis [2] and cystic fibrosis [3]. Whether adding macrolide therapy to the antibiotic regimen in patients with sepsis and CAP will result in a better outcome cannot be concluded from the study performed by RESTREPO *et al.* [1]. Their nonrandomised study did not provide information regarding clinical decisions such as why some patients were given macrolide therapy and others were not. Moreover, we are not informed about the presence of infections caused by *Legionella pneumophila* type 1 which are relatively common in patients with severe CAP [4]. Adding macrolide therapy is one of the choices of treatment in infections caused by this microorganism.

The conclusion of RESTREPO *et al.* [1] recommended further prospective studies. In 2005, we published a prospective randomised study in which we compared a pathogen-directed therapy, based on monotherapy, with an empirical approach consisting of a betalactam antibiotic and a macrolide in patients with CAP [5]. In that study, we showed that both treatment regimes resulted in comparable efficacy. In patients with severe CAP who were referred to the intensive care unit, combination treatment, including a macrolide and a betalactam antibiotic, resulted in a significantly higher mortality rate. Although this group of patients was relatively small, we are not convinced that adding macrolide therapy to patients with

CAP will result in the same beneficial effects as seen in chronic inflammatory airway diseases such as cystic fibrosis and diffuse panbronchiolitis, unless atypical pathogens sensitive for macrolide therapy are present. Concerning the increasing rate of microbial resistance due to antibiotic overuse, we need to be very careful when deciding to add macrolide therapy for immunomodulation reasons in patients with CAP.

M.M. van der Eerden* and W.G. Boersma#

*Erasmus Medical Centre, Rotterdam, and #Medical Centre Alkmaar, Alkmaar, The Netherlands.

Correspondence: M.M. van der Eerden, Medical Centre Alkmaar, Wilhelminalaan 12, Alkmaar 1815 JD, The Netherlands. E-mail: mvaneerden@yahoo.com

Statement of Interest: None declared.

REFERENCES

- 1 Restrepo MI, Mortensen EM, Waterer GW, *et al.* Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. *Eur Respir J* 2009; 33: 153–159.
- 2 Nagai H, Shishido H, Yoneda R, *et al.* Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. *Respiration* 1991; 58: 145–149.
- 3 Equi A, Balfour-Lynn IM, Bush A, *et al.* Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. *Lancet* 2002; 360: 978–984.
- 4 Stout JE, Yu VL. Legionellosis. *N Engl J Med* 1997; 337: 682–687.
- 5 van der Eerden MM, Vlasplolder F, de Graaff CS, *et al.* Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. *Thorax* 2005; 60: 672–678.

DOI: 10.1183/09031936.00036209

Paradoxical movement of the lower ribcage in COPD

To the Editors:

The paper by ALIVERTI *et al.* [1], which appeared in a recent issue of the *European Respiratory Journal*, suggests that the presence of paradoxical movement of the lower ribcage at rest in chronic obstructive pulmonary disease (COPD) patients is associated with early onset hyperinflation of the chest wall and predominant dyspnoea at end exercise. ALIVERTI *et al.* [1] stated

that this paradoxical movement has not been related to other forms of respiratory behaviour or symptoms.

However, this is not exact since my group has evaluated the frequency and clinical characteristics of the paradoxical movement of the lower ribcage (classically, Hoover's sign) in patients with COPD. Hoover's sign is easy to recognise and has a good interobserver agreement [2]; it is a frequent finding in